Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Subscribe To Our Newsletter & Stay Updated
